Online Medical Marijuana & CBD Dispensary Directory Provides Patients with User-Friendly Cannabis App to Identify Products, Various Strains & Dispensary Locations
CORAL SPRINGS, Florida, October 7, 2014 /PRNewswire/ —
Biotech and Pharmaceutical companies focus on the development and commercialization of therapeutics for patients with infectious diseases as well as forecasts project legal medical marijuana sales to reach $3 billion by year’s end, up $1.5 billion from 2013. Biotech & Biopharceutical Companies in Focus today are: Earth Science Tech, Inc. (OTC: ETST), INSYS Therapeutics, Inc. (NASDAQ: INSY), Durata Therapeutics, Inc. (NASDAQ: DRTX), GW Pharmaceuticals plc (NASDAQ: GWPH) and Nuvilex, Inc. (OTC: NVLX)
Earth Science Tech, Inc. (OTCQB: ETST) a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced an update on its wholly owned subsidiary Leafstrain.com. ETST is pleased to announced that Version: 1.0 of its Leafstrain.com mobile application, for use on iOS devices including iPhone, iPod Touch and iPad, is now available for immediate Free download in the iTunes APP Store using the following link: https://itunes.apple.com/us/app/leafstrain-cannabis-strains/id906031084?mt=8
To read the full ETST press release, please click here: http://www.financialnewsmedia.com/profiles/etst.html
Users can also find it by simply searching the iTunes App store using the key word search”Leafstrain.com.” ETST is extremely enthusiastic to be approved and now listed in Apple (NASDAQ: AAPL) iTunes as an approved developer and now having its first iOS mobile application “Leafstrain.com” ready for download. ETST new dynamic Leafstrain.com mobile iOS app can be downloaded free of charge and installed in the user’s mobile device of choice. Using the Leaftsrain.com app, users can leverage the power of iOS mobile devices by turning them into an amazing handheld information center while they are on the go (mobile). This will allow patients and users to connect, search, find, share, review, comment and map the best Cannabis strains and dispensaries plus more. Right from a mobile device, users can search the Leafstrain.com Social Network and Online Community as well as its large online database of 3,000+ Medical Marijuana dispensaries and Cannabis 300+ strains. Users can use their zip code or city and state names to search for dispensaries, which are then displayed on a map of the area. The dispensary profiles contain store locations, hours, photos, reviews and much more. ETST believes this community, Leafstrain.com, can become an industry leader and premier Medical Marijuana & Cannabis Community on the web, catering to the entire industry from patients to businesses.
INSYS Therapeutics, Inc. (NASDAQ: INSY) Dronabinol Oral Solution is an orally-administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC), which may offer advantages over Dronabinol SG, including more consistent bioavailability, faster onset of action and more flexible dose titration. The FDA granted Insys Orphan Drug Designation for use of pharmaceutical cannabidiol, or CBD, for the treatment of both Lennox-Gastaut Syndrome and Dravet Syndrome, two rare forms of epilepsy in children, and for the treatment of glioblastoma multiforme, an aggressive and often incurable form of brain cancer. Insys plans to file an IND for CBD in the second half of 2014. The company recently submitted its NDA for Dronabinol Oral Solution, a novel formulation which has the potential to offer distinct advantages over existing generic capsules including a faster rate of absorption, more consistent blood levels, and the ability to titrate to effect.
Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. On Monday, DRTX closed up 74.64% on over 7.9 million shares traded.
GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, provided the following details regarding its upcoming Research and Development Day scheduled for 14 October, 2014: Location: New York City. Date: 14 October, 2014. Time: Registration begins at 9:30 a.m. ET, program from 10:00 a.m. ET — 1:00 p.m. ET. Agenda: The program will provide an update on GW’s product pipeline and is expected to include presentations on the science and application of cannabinoids, updated data from the Epidiolex(R) epilepsy expanded access program, and a review of current pipeline programs including initial data from GW’s ulcerative colitis Phase 2a clinical trial.
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, recently announced that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of Nuvilex’s newly formed Scientific Advisory Board. Dr. Lohr has been a full professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden, since 2007. He has served as Professor of Molecular Gastroenterology at the University of Heidelberg and was the Head of the Molecular Gastroenterology Unit at the German Cancer Research Center. Dr. Lohr has also worked as a translational scientist and Principal Investigator in clinical studies in gastrointestinal oncology for many years and completed a postdoctoral fellowship at the Scripps Clinic & Research Foundation in La Jolla, California. After receiving his M.D. degree, Dr. Lohr served a residency in pathology and a residency in internal medicine and gastroenterology in Erlangen and Rostock in Germany, where he also served as an Assistant Professor.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by Earth Science Tech, Inc. by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
The post Online Medical Marijuana & CBD Dispensary Directory Provides Patients with User-Friendly Cannabis App to Identify Products, Various Strains & Dispensary Locations appeared first on Marijuana Investor News.